Study of P3914 to Evaluate the Safety, Tolerability, Food Effect & Pharmacokinetics in Healthy Male Subjects and Efficacy & Safety of P3914 in Patients With Acute Dental Pain

NCT01339156 | Terminated Phase 1

• 1 other identifier: P3914/48/10
• Study Type: interventional
• Target: 46
• Locations: 0 countries
• Sites: N/A

Brief Summary

P3914 a pro-drug of Naproxen, characterized by naproxen (COX inhibiting moiety) linked to a NO moiety is intended for the treatment of pain and inflammation. The rationale behind development of P3914 is to maintain the analgesic, antipyretic and anti-inflammatory activity of naproxen and enhance GI safety by virtue of release of NO besides with no major effect on blood pressure on long-term administration.

Conditions

Acute Dental Pain

Keywords

Safety; Tolerability; Food Effect; Pharmacokinetics

Outcome Measures

Primary Outcomes (1)

• Vital signs- systolic and diastolic blood pressure, pulse rate and oral body temperature.

  Vital signs will be measured using DASH 4000. Predose vital signs will be recorded within 30 minutes prior to dosing. Part A: pre-dose \& at 1,2,3,4,5,6,8,12,16,24,48,72,96 \& 120 hrs post dose. Part B:pre-dose on Day 2 to Day 13,predose \& at 4 and 12 hrs post-dose on Days 1 \&14.Part:C: pre-dose \& at 1, 2, 3, 4, 5,6,8,12,24,48,72,96 \& 120 hrs postdose.Part D:predose \& at 0.5,1,2,4,\&8 hrs post dose.

  Defined in description

Secondary Outcomes (5)

• Pain intensity using 100 mm Visual analog scale

  immediately before administration of study drug and at 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 5.00, 6.00, 7.00, and 8.00 hrs post-dose, and immediately before administration of rescue analgesia (if any).

• Pharmacokinetic assessment for Part A

  within 15 min prior to dosing. Post-dose blood samples will be drawn at 0.25, 0.50, 1, 2, 3, 3.50, 4, 4.50, 5, 5.50, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96 & 120 hrs following drug administration.

• Pharmacokinetic assessment for Part C

  within 15 min prior to dosing. Post-dose samples will be drawn at 0.25, 0.50, 1, 2, 3, 3.50, 4, 4.50, 5, 6, 8, 10, 12, 24, 48, 72, 96 & 120 hrs following drug administration.

• Pharmacokinetic assessment for Part B

  within 15 min prior to dosing on Day 1, 6, 9, 13&14. Post-dose blood samples at 0.25, 0.50, 1, 2, 3, 3.50, 4, 4.50, 5, 5.50, 6, 8, 10, 12, 16& 24 hrs following drug administration on Day 1 & Day 14 and 48 hrs post-dose on Day 16

• Pharmacokinetic assessment for Part D

  within 15 min prior to dosing. Post-dose blood samples of at 0.50, 1, 2, 3, 3.50, 4, 4.50, 5, 5.50, 6 and 8 hrs following drug administration

Study Arms (2)

P3914

EXPERIMENTAL

Drug: P3914

Placebo

PLACEBO COMPARATOR

Drug: Placebo

Interventions

P3914 DRUG

Part A: The subjects will be fasted overnight for at least 10 hrs.The drug will be administered orally to each subject in sitting posture. Part B: Dosing will start on Day 1. Each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14). The investigational product will be administered orally to each subject with 240 mL of water. Part C: Dosing will take place on Day 1 of each study period. Each subject will receive a single oral dose. For administration of P3914 tablets subjects will be required to fast for 10 hrs prior to dosing. Part D: Patients will be fasted for at least 4-6 hrs. The investigational product will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery).

P3914

Placebo DRUG

Part A: The subjects will be fasted overnight for at least 10 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture. Part B: Dosing will start on Day 1. It is planned that each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14). The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject with 240 mL of water. Part D: Patients will be fasted for at least 4-6 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery).

Placebo

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• for Part A, Part B and Part C
• Male subjects aged between 18 and 45 years (including both) with Body Mass Index between 18 to 25 kg/m2 (including both).
• Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable normal range.
• Subjects having clinically acceptable 12-lead electrocardiogram (ECG).
• Subjects having clinically acceptable X-Ray chest (P/A view).
• Subjects having clinically acceptable endoscopy.
• Have a negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
• Have negative alcohol breath test.
• Subjects willing to adhere to the protocol requirements and to provide written informed consent.
• Part D:
• Patients with acute postoperative dental pain (at least moderate in severity or score of 40 mm on VAS) after removal of an impacted third mandibular molar will be selected for study participation, if they meet the following criteria:
• Male patients aged between 18 and 60 years (including both).
• Patients with acute postoperative dental pain (at least moderate in severity or score of 40 mm on Visual Analogue Scale)
• Patients with otherwise normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable normal range.
• Patients having clinically acceptable 12-lead electrocardiogram (ECG).

You may not qualify if:

• Part A, Part B and Part C:
• Hypersensitivity to NSAIDs or nitrodonating drugs.
• History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
• Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within one month of the study starting.
• History or presence of significant gastric and/or duodenal ulceration including the last three months or gastroduodenal bleeding including the last six months prior to the screening visit.
• History of peptic ulceration or significant dyspepsia as judged by the investigator.
• Endoscopy finding of gastric or duodenal ulcer at baseline. Erosive esophagitis or other endoscopic appearance that constitutes a risk to the subject, if included in the study, as judged by the investigator.
• Have positive test for Helicobacter pylori infection.
• Orthostatic hypotension with a systolic blood pressure drop of ≥ 25 mm Hg and/or a diastolic blood pressure drop of ≥ 15 mm Hg within 5 minutes of standing when changing from supine to erect position.
• A history of renal impairment, or a glomerular filtration rate (GFR) \<60 mL/min or, at visit 1, a serum creatinine value \>140 mol/L.
• Use of aspirin, H2 antagonists, antacids, misoprostol, proton pump inhibitors, sucralfate including two weeks prior to the screening visit.
• Subjects currently taking sildenafil, anticoagulants or ticlopidine, nitrates, nitrovasodilating drugs (e.g. nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, glycerin trinitrate), diuretics (in a dose potentially leading to volume depletion).
• Use of any prescribed medication during last two weeks or OTC medicinal products (including herbal/traditional medicine preparations) during the last one week prior to initiation of study.
• History or presence of significant alcoholism or drug abuse in the past one year.
• Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.

Sponsors & Collaborators

• Piramal Enterprises Limited: lead

Study Officials

• Dr. Dharmesh Domadia

  Veeda Clinical research private limited

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 15, 2011
• First Posted: April 20, 2011
• Study Start: June 1, 2011
• Primary Completion: November 1, 2011
• Study Completion: June 1, 2012
• Last Updated: November 22, 2012

Record last verified: 2012-11